Clinical Trial Update: Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating a Gemcitabine, Oxaliplatin, Sintilimab, and Bevacizumab combination in unresectable biliary tract cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Gemcitabine (Gemcitabine)
• OXALIPLATIN (Oxaliplatin)
• Sintilimab (sintilimab)

Snippet

Sponsor: Fudan University | Conditions: Biliary Tract Carcinoma, Initially Unresectable | Phase 2 | Status: UNKNOWN